News

Glaucoma is a leading cause of blindness, a problem which is made even more serious by the fact that many patients do not notice any symptoms until it is too late to prevent permanent blindness.

Humans are creatures of habit, even ophthalmologists. Having learned to use one device for pupil expansion, it is easy to forget that there are alternative devices.

There was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin-known as the Dropless approach-in addition to an NSAID after cataract surgery.

A 59-year-old otherwise healthy man presented with an acute-onset diffuse rash involving over 90% of his body surface area, including oral, genital, and ocular mucosal involvement. Initial ophthalmic examination was notable for development of extensive corneal epithelial defects in both eyes as well as conjunctival sloughing and pseudomembrane formation.

As the end of the year approaches, we wanted to take a look back at the predictions our Editorial Advisory Board members made for 2016 and see how far we’ve come in the last 12 months.

Looking back over the past year and into the near future, Eric D. Donnenfeld, MD, Robert H. Osher, MD, and Mark Packer, MD, spoke to Ophthalmology Times about developments in diagnostic products and other tools used in cataract surgery. In addition, they discussed combination microinvasive glaucoma surgery (MIGS) and office-based surgery as new trends.

Cataract surgeons in the United States have long been envious of the IOL options available to their international colleagues. Finally, in 2016, American ophthalmologists gained access to some novel IOLs such as the Tecnis Symfony Extended Range of Vision IOL and the Tecnis Symfony Toric IOL (Abbott) that were approved by the FDA. According to leading cataract surgeons who spoke to Ophthalmology Times, these simultaneous approvals rank as the biggest cataract surgery news story of the year.

A single event stood out in everyone’s mind when Ophthalmology Times asked experts to think back on the year in glaucoma surgery: the July 29 approval by the U.S. Food and Drug Administration (FDA) of the CyPass Micro-Stent.

As we sit down together with our families and friends for Thanksgiving dinner this year, we thought reflecting on the great innovations in the field of ophthalmology since the turn of this new century seemed timely (a topic that is a natural by-product of the marriage between a retinal surgeon and a pediatric ophthalmologist!).

A case of cataract surgery with planned presbyopia-correcting IOL implantation– complicated by posterior capsule rupture and a postoperative refractive surprise– reinforced important lessons and provided a new revelation to one experienced surgeon.

Findings from an updated analysis of outcomes at a single center reaffirm the safety of femtosecond laser capsulotomy by showing it is associated with a low rate of anterior capsule tears.

Not long ago, whilst on my way to work, I found myself listening to one of those call-in doctor radio programs. People gave their first names and then described some problem they, a family member, or a friend were experiencing. The all-knowing medical expert would then ask a few questions and steer the caller in a certain direction.

Research. Industry. Philanthropy. These three facets-each with a unique purpose-will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.

Despite growing profits over a decade, an ophthalmic practice’s optical dispensary profits were not growing along the same curve. This case study highlights how an optical dispensary inventory management firm may be able to identify strategies to boost capture-rate underperformance.